A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

• Status: Not yet recruiting
• Trial end date: 2024-10-23
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 11 weeks excluding the screening period.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Tirzepatide

Criteria

Inclusion Criteria:

• Male and female participants with obesity

• Participants with screening body weight ≥ 50 kilogram (kg) for cohort 1 and < 50 kg for cohorts 2 and 3.

• Participants with body mass index (BMI) ≥ the 95th percentile for age and sex

Exclusion Criteria:

-